Human Studies

Human Clinical Trials
It is important to note that many studies have been conducted testing NR in various animal models. In 2015, the first human clinical studies were completed and the results demonstrated that NR safely and effectively boosts levels of NAD in healthy human volunteers.

In addition to these studies, there are approximately 13 additional human clinical trials studying NR in various endpoints which are currently underway or have recently completed. We anticipate completion of many of these trials over the next year or so. To track some of the progress on many of these studies, visit clinicaltrials.gov.

Estimated
Completion

Human Studies

completedPublished in Nature Communications A Study of the Pharmacokinetics of Three Dosages of Niagen® in Healthy Subjects

Dartmouth University; KGK Synergize Inc.
(participants n=1, n=12)
Dose: 100mg, 300mg, & 1,000mg
See Full Abstract

completedNot Yet Published Pharmacokinetic Study of Nicotinamide Riboside

University of Washington
(participants n=8)
Dose: 250mg, 500mg, & 1,000mg
See Full Abstract

completedSubmitted for Publication Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults

University of Colorado, Boulder; ChromaDex Inc.
(participants n=30)
Dose: 250mg, 500mg, & 1,000mg
See Full Abstract

completedNot Yet Published A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects

Elysium Health; KGK Synergize Inc.
(participants n=120)
Dose: 250mg, 500mg & placebo
See Full Abstract

completedNot Yet Published Pharmacokinetic Analysis of Nicotinamide Riboside

Aarhus University Hospital; University of Copenhagen
(participants n=12)
Dose: 500mg & 1,000mg
See Full Abstract

completedNot Yet Published A Study Investigating the Effects of Niagen® in Healthy Adults

KGK Synergize Inc.; ChromaDex
(participants n=140)
Dose: 100mg, 300mg, 1,000mg & placebo
See Full Abstract

Spring 2017 Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

National Heart, Lung & Blood Institute
(participants n=58)
Dose: 1,000mg & placebo
See Full Abstract

Spring 2017 The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men

Aarhus University Hospital; University of Copenhagen
(participants n=40)
Dose: 1g & placebo
See Full Abstract

Fall 2017 Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Football Players

Mayo Clinic; University of Minnesota – Clinical and Translational Science Institute; Thorne Research Inc.
(participants n=48)
Dose: 3 capsules & placebo
See Full Abstract

Winter 2017 (In design) The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

The University of Texas Health Science Center at San Antonio; University of Texas; South Texas Veterans Health Care System
(participants n=26)
Dose: 250mg, 500mg, 750, 1g & placebo
See Full Abstract

Spring 2018 Nicotinamide Riboside and Metabolic Health

Maastricht University Medical Center; Dutch Heart Foundation
(participants n=15)
Dose: 1,000mg & placebo
See Full Abstract

Fall 2018 Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study (BAKIS)

Massachusetts General Hospital; Elysium Health
(participants n=6)
Dose: Basis Formula (250mg NR, 50mg pterostilbene) & placebo
See Full Abstract

Summer 2019 The Effects of Nicotinamide Riboside Supplementation on NAD+/NADH Ratio and Bioenergetics

Mclean Hospital
(participants n=60)
Dose: 1,000mg
The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain NAD+/NADH ratio and bioenergetics functions in healthy individuals using phosphorus magnetic resonance spectroscopy (31P MRS) imaging.

The secondary aim is to investigate the effects of NR on brain structure and neurotransmitter functions using other neuroimaging methods.
See Full Abstract

Fall 2019 Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)

University of Birmingham
(participants n=12)
Dose: 1,000mg & placebo
See Full Abstract

8/2/2017 – Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.